Do I need an in-person exam for Wegovy in California?

If you’ve been considering medications like Wegovy, Ozempic, or Mounjaro for weight loss but aren’t sure whether you can get them through telehealth, you’re not alone. Millions of Americans are exploring online options for obesity treatment—and the good news is that yes, you can legally obtain GLP-1 weight loss medications through telehealth in the United States.

However, the rules vary by state, and understanding what’s required can feel overwhelming. This guide breaks down everything you need to know about accessing these powerful medications remotely, from federal regulations to state-specific requirements, provider qualifications, and what to expect during your telehealth visit.

Understanding the Basics: Federal Law and Telehealth Prescribing

GLP-1 Medications Are Not Controlled Substances

Here’s the most important thing to know: weight loss medications like Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are not federally controlled substances. This distinction matters because the Ryan Haight Act—a federal law requiring an in-person visit before prescribing controlled medications—does not apply to these drugs.

Unlike stimulant medications such as Adderall or phentermine (older appetite suppressants), GLP-1 agonists fall outside the DEA’s strict telehealth prescribing rules. This means that under federal law, a licensed healthcare provider can evaluate you via video consultation and send your prescription electronically to a pharmacy without ever meeting you face-to-face.

COVID-Era Telehealth Flexibilities Remain in Effect

During the pandemic, federal regulators temporarily relaxed prescribing rules even for controlled substances. As of December 2025, the DEA has extended these telehealth flexibilities through December 31, 2025, giving providers additional time to craft permanent regulations. While this extension primarily affects controlled medications (like ADHD stimulants or certain pain medications), it reflects the government’s broader acceptance of telehealth as a legitimate care delivery model.

The bottom line: Telehealth for weight loss medications is not only legal—it’s become standard practice, with robust regulatory support at the federal level.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

How State Laws Affect Your Access to Telehealth Weight Loss Treatment

While federal law provides the foundation, state regulations determine the specific requirements for prescribing weight loss medications via telehealth. Some states have minimal restrictions, while others require initial in-person visits or impose additional oversight measures.

States With No In-Person Requirements

Several states allow complete telehealth-based care for obesity medications without mandating any face-to-face visits:

• California
• Connecticut
• Illinois
• New York
• Pennsylvania
• Washington

In these states, your entire treatment journey—from initial consultation through ongoing refills—can happen virtually, as long as your provider follows appropriate clinical standards.

States Requiring an Initial In-Person Exam

Other states mandate at least one in-person physical examination before or shortly after starting telehealth weight loss treatment:

• Arkansas – Must perform first exam in-person
• Delaware – Initial physical exam required
• Georgia – In-person exam required prior to telehealth prescribing
• Mississippi – Initial in-person evaluation mandated
• New Jersey – Comprehensive in-person exam plus labs required
• North Dakota – Hands-on initial evaluation expected
• South Carolina – Must examine patient in person first
• Texas – In-person exam generally expected prior to telehealth prescriptions
• Utah – Initial in-person exam encouraged
• Virginia – Must perform physical exam and labs initially

These requirements reflect each state’s medical board policies around establishing a proper patient-provider relationship and ensuring thorough evaluation before starting powerful medications.

States With Ongoing Monitoring Requirements

Beyond initial visits, some states impose regular follow-up requirements:

Florida requires patients to:

• Have a BMI of 30 or higher
• Complete follow-up visits at least every 3 months during treatment

Virginia mandates:

• Initial physical exam and lab work
• A personalized diet and exercise plan
• Follow-up within 30 days of starting therapy

Connecticut requires:

• Behavioral counseling as part of treatment
• Diet and exercise planning

These rules ensure that weight loss medications are used as part of comprehensive lifestyle intervention, not as standalone ‘quick fixes.’

Who Can Prescribe Weight Loss Medications via Telehealth?

Medical Doctors and Doctors of Osteopathy

All states allow licensed MDs (Medical Doctors) and DOs (Doctors of Osteopathy) to prescribe GLP-1 medications via telehealth, provided they hold an active license in the state where the patient is physically located during the consultation.

Nurse Practitioners: Varying Levels of Authority

Nurse Practitioners (NPs) can prescribe weight loss medications in all 50 states, but their level of independence varies significantly:

Full Practice Authority States (NPs can prescribe independently):

• California (after 3+ years experience)
• Connecticut (after 3 years collaboration)
• Delaware (after 2 years collaboration)
• New York (after 3,600 hours supervised practice)
• Utah (full practice as of 2023)
• Virginia (autonomous after 2 years)
• Washington (fully independent)

Collaborative/Supervised Practice States (NPs require physician oversight):

• Arkansas (APRN must have MD agreement)
• Florida (collaborative agreement required)
• Georgia (MD protocol required; new 2024 law allows Schedule II with agreement)
• Illinois (written MD agreement required)
• Mississippi (MD collaboration required)
• New Jersey (joint protocol with physician)
• North Dakota (collaborative initially, then independent)
• Pennsylvania (collaboration required, pending regulatory changes)
• South Carolina (MD supervision with written protocol)
• Texas (physician delegation required; no full practice authority)

What this means for patients: You may see an NP or PA during your telehealth consultation. This is completely normal and legal—these providers undergo extensive training in prescribing and obesity management. At Klarity Health, we ensure all providers are appropriately licensed and credentialed in your state, operating within their scope of practice.

Physician Assistants

Physician Assistants (PAs) can also prescribe GLP-1 medications for weight loss in every state, though they typically require a collaborative agreement or supervisory relationship with a physician. The specific arrangement depends on state law—some allow substantial autonomy, while others require closer oversight.

Understanding the Medications: Wegovy, Ozempic, and Mounjaro

What Are GLP-1 Receptor Agonists?

These medications work by mimicking a natural hormone (glucagon-like peptide-1) that regulates appetite, slows stomach emptying, and helps control blood sugar. The result: you feel fuller longer, eat less, and lose weight gradually over time.

Supply and Refills

Because these medications aren’t controlled substances, there are no federal limits on prescription quantities. However, prescribing practices vary:

• Initial prescriptions: Often 4 weeks (one month) to assess tolerance and response
• Ongoing prescriptions: May extend to 90-day supplies if patient is stable
• Refills: Many telehealth programs authorize refills but schedule regular check-ins (monthly or quarterly) to monitor progress and side effects

The Compounding Ban: What Changed in 2025

In May 2025, the FDA declared the Wegovy/Ozempic shortage resolved and banned most retail compounding of semaglutide for weight loss. This affected some telehealth companies offering cheaper compounded versions. Today, legitimate telehealth providers prescribe only FDA-approved, brand-name medications dispensed through licensed pharmacies.

Red flag: Be cautious of any service offering ‘compounded semaglutide’ or overseas versions—these may not meet FDA safety standards and could be illegal.

What to Expect During Your Telehealth Weight Loss Consultation

Initial Evaluation Process

A legitimate telehealth provider will require:

1. Detailed Medical History

• Current and past health conditions
• Family history (especially thyroid cancer, which is a contraindication)
• Current medications and supplements
• Allergies

1. Physical Measurements

• Current height and weight (often self-reported, sometimes verified)
• BMI calculation
• Blood pressure (if available)

1. Lifestyle Assessment

• Diet and exercise habits
• Previous weight loss attempts
• Weight loss goals and motivation

1. Mental Health Screening

• History of eating disorders
• Depression or anxiety (which may affect treatment)
• Substance use

1. Video Consultation

• Live discussion with licensed provider (typically 15-30 minutes)
• Review of medical history and treatment options
• Discussion of risks, benefits, and alternatives
• Informed consent process

Clinical Eligibility Criteria

To qualify for GLP-1 weight loss medications, you generally must meet these criteria:

• BMI ≥30 (obesity), OR
• BMI ≥27 with at least one weight-related comorbidity (such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea)
• Age 18 or older (pediatric use requires in-person care)
• No contraindications (see below)

Contraindications and Red Flags

You will not qualify for these medications if you have:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning to become pregnant (must discontinue 2 months before conception)
• Active gallbladder disease or history of severe gallstones
• History of pancreatitis
• Severe gastroparesis or digestive disorders
• Allergies to semaglutide or tirzepatide

Reputable providers carefully screen for these conditions during your intake.

The Treatment Plan: Beyond Just Medication

Quality telehealth programs don’t just hand you a prescription. They provide:

• Lifestyle Counseling: Diet and exercise recommendations tailored to your goals
• Regular Follow-ups: Scheduled video visits (often at 1 month, then every 2-3 months)
• Side Effect Monitoring: Tracking nausea, GI upset, and other common reactions
• Dose Titration: Gradual increase in dosage to minimize side effects and optimize results
• Lab Monitoring: Periodic metabolic panels, A1C checks (especially if diabetic), and lipid panels
• Patient Education: Training on self-injection technique, storage, and disposal

This comprehensive approach aligns with medical board standards and ensures you receive safe, effective care.

What About Insurance Coverage?

Coverage for GLP-1 weight loss medications varies widely:

• Many commercial insurance plans now cover Wegovy or Zepbound, especially with prior authorization demonstrating medical necessity
• Medicare does not currently cover weight loss medications (though this may change with pending legislation)
• Medicaid coverage varies by state
• Cash-pay options are available through most telehealth platforms

At Klarity Health, we accept both insurance and cash pay, with transparent pricing so you know your costs upfront. Our team can verify your insurance benefits and help you understand your out-of-pocket expenses before starting treatment.

Klarity Health: Accessible, Transparent Telehealth for Weight Management

When you’re ready to explore weight loss medications through telehealth, choosing the right provider matters. At Klarity Health, we’ve built our practice around three core principles:

1. Provider Availability When You Need It

We maintain a network of licensed MDs, DOs, NPs, and PAs across multiple states, ensuring you can schedule consultations quickly—often within days, not weeks. Our providers are experienced in obesity medicine and stay current on evolving state regulations.

2. Transparent Pricing You Can Trust

No hidden fees or surprise charges. Whether you’re using insurance or paying cash, we provide clear pricing before your visit. You’ll know exactly what to expect, from consultation fees to medication costs.

3. Both Insurance and Cash Pay Options

We work with most major insurance plans and offer competitive cash-pay rates for those without coverage or with high deductibles. Our goal is to remove financial barriers to effective weight management care.

Common Misconceptions About Telehealth Weight Loss Treatment

Myth #1: ‘Anyone can get these medications online easily’

Reality: Legitimate telehealth providers conduct thorough medical evaluations. If you don’t meet clinical criteria (BMI requirements, absence of contraindications), a reputable provider will decline to prescribe and recommend alternative approaches.

Myth #2: ‘Telehealth weight loss programs are just ‘pill mills”

Reality: Quality telehealth obesity care follows the same standards as in-person treatment. Providers must document comprehensive evaluations, obtain informed consent, monitor for side effects, and coordinate with your other healthcare providers when appropriate.

Myth #3: ‘These are ‘diet pills’ that work overnight’

Reality: GLP-1 medications support gradual, sustainable weight loss over months—not days. Typical results are 10-15% body weight reduction over 6-12 months when combined with lifestyle changes. They require patience and commitment.

Myth #4: ‘State laws make telehealth prescribing too complicated’

Reality: While state rules vary, experienced telehealth providers navigate these requirements seamlessly. As a patient, you simply need to ensure you’re working with a properly licensed provider in your state—the rest is handled behind the scenes.

Myth #5: ‘Telehealth means no accountability or follow-up’

Reality: Structured telehealth programs schedule regular video check-ins, track your progress, adjust dosing as needed, and provide ongoing support. Many patients find telehealth more convenient for consistent follow-through compared to in-person appointments.

Red Flags: How to Spot Questionable Telehealth Services

As the demand for weight loss medications has surged, unfortunately some less-than-reputable operators have entered the space. Protect yourself by watching for these warning signs:

🚩 Guaranteed Prescriptions: Any service promising you’ll get a prescription without a proper medical evaluation

🚩 Compounded or Overseas Medications: Offers of ‘cheaper alternatives’ to FDA-approved drugs, especially from foreign sources

🚩 No Live Provider Interaction: Services that rely solely on questionnaires without video or phone consultations

🚩 Missing Credentials: Unclear about provider licensing or unwilling to share credentials

🚩 No Follow-up Required: Prescribing without scheduling monitoring visits or assessing progress

🚩 Skipping Informed Consent: Failing to discuss risks, side effects, contraindications, and alternatives

🚩 Lacks Physical Presence: No verifiable clinic address, phone number, or state licensure information

Choose established telehealth platforms with transparent practices, licensed providers, and comprehensive care models. Klarity Health meets all regulatory standards and prioritizes patient safety above all else.

The Future of Telehealth Weight Loss Treatment

The regulatory landscape continues to evolve in ways that favor expanded access:

Federal Policy Trends

• The DEA has signaled likely extension or permanence of telehealth prescribing flexibilities beyond 2025
• The TREATS Act (reintroduced in October 2025) seeks to permanently authorize certain telehealth prescribing without in-person visits, reflecting bipartisan support for virtual care
• Medicare and commercial insurers are expanding telehealth coverage, including for obesity counseling and potentially medications

State-Level Developments

• More states are adopting full practice authority for nurse practitioners, expanding the provider workforce for telehealth obesity care
• States are streamlining licensure through interstate compacts, making it easier for providers to serve patients across state lines
• COVID-era temporary waivers are being codified into permanent law in many jurisdictions

Clinical Innovation

• New anti-obesity medications are in development, offering more options beyond semaglutide and tirzepatide
• Combination therapies and longer-acting formulations may reduce injection frequency
• Integration of remote patient monitoring (connected scales, continuous glucose monitors) with telehealth platforms will enable even more personalized care

The trajectory is clear: Telehealth for weight management is becoming more accessible, more regulated (in good ways that protect patients), and more sophisticated in its clinical approach.

Frequently Asked Questions

Do I need to live in the same state as my telehealth provider?

No—but your provider must be licensed in the state where you physically are during the consultation. Most telehealth platforms, including Klarity Health, employ or contract with providers licensed in multiple states to serve patients nationwide.

Can I use telehealth if my state requires an initial in-person visit?

Yes. In states with this requirement, you can complete your initial exam at a local clinic or with your primary care physician, then transition to telehealth for ongoing management. Some telehealth companies also have partnerships with local clinics to facilitate these in-person visits when needed.

How long does it take to get a prescription after my consultation?

If you qualify, your provider typically sends the prescription electronically to your chosen pharmacy the same day. Depending on pharmacy stock and insurance processing, you may receive your medication within 1-3 days.

What if I experience side effects?

Contact your telehealth provider immediately. Most platforms offer secure messaging or nurse support lines between scheduled visits. Common side effects (nausea, constipation) often improve with dose adjustment or supportive care. Serious side effects warrant stopping the medication and seeking evaluation.

Can I switch from in-person to telehealth care (or vice versa)?

Absolutely. Many patients start with telehealth for convenience, then transfer to in-person care if they prefer—or the reverse. Your medical records can be shared (with your consent) to ensure continuity of care.

Will my regular doctor know I’m taking these medications?

Yes, if you authorize it. Telehealth providers should coordinate with your primary care physician and send visit summaries. This is especially important if you have other chronic conditions like diabetes or heart disease.

Are these medications safe long-term?

GLP-1 medications have been studied for several years with favorable safety profiles. However, they’re relatively new for obesity treatment, and most patients use them for 1-2 years while establishing sustainable lifestyle changes. Long-term use (beyond 2 years) is being studied. Your provider will discuss the risks and benefits for your individual situation.

Can I get these medications if I just want to lose a few pounds for cosmetic reasons?

Probably not through a reputable provider. These powerful medications are FDA-approved for medical weight management in patients with obesity or significant weight-related health risks—not for cosmetic weight loss in otherwise healthy individuals. Your provider will assess whether you truly have a medical indication.

Take the Next Step Toward Your Weight Loss Goals

If you’ve struggled with weight management despite diet and exercise, and you meet the clinical criteria for GLP-1 therapy, telehealth offers a convenient, effective, and fully legal pathway to get the care you need.

Understanding the regulations—both federal and state-specific—empowers you to make informed decisions and choose a telehealth provider you can trust. While state rules vary in their details, the fundamental truth remains: you can absolutely access evidence-based weight loss medications through telehealth with proper medical oversight.

Why Choose Klarity Health

At Klarity Health, we combine clinical excellence with patient-centered convenience:

• Fast Access: Schedule consultations quickly with experienced providers
• Transparent Costs: Know your expenses upfront—no surprises
• Flexible Payment: We accept most insurance plans and offer cash-pay options
• Comprehensive Care: Beyond prescriptions, we provide ongoing support, monitoring, and lifestyle coaching
• Multi-State Availability: Licensed providers serving patients across the U.S.

Ready to get started? Visit Klarity Health to schedule your confidential telehealth consultation and take the first step toward sustainable weight loss with medical support.

Whether you’re in California or Connecticut, Texas or Washington, the path to effective weight management through telehealth is open—and we’re here to guide you every step of the way.

References and Additional Resources

Verified as of: December 17, 2025

Top 5 Citations:

1. DEA and HHS Extend Telemedicine Flexibilities Through 2025 – DEA.gov official announcement (Nov 15, 2024). Confirms federal telehealth rules for controlled substances remain in effect through December 31, 2025. www.dea.gov

2. Axios News: COVID Telehealth Prescribing Extended – Axios reporting (Nov 18, 2024) on the DEA’s third one-year extension of pandemic-era telehealth flexibilities for prescribing controlled medications. www.axios.com

3. Goodwin Procter Legal Alert: Changing Regulatory Landscape of Weight-Loss Drugs – Comprehensive analysis (Mar 27, 2024) of state-specific requirements for prescribing obesity medications, including Florida, New Jersey, and Virginia rules. www.goodwinlaw.com

4. McDermott Will & Emery: DEA Extends Telemedicine Flexibilities – Legal analysis (Nov 18, 2024) explaining the Ryan Haight Act, DEA’s temporary waivers, and implications for telehealth prescribing. www.mwe.com

5. Reuters: FDA Bans Weight Loss Drug Copies, Hims Cuts Workforce – News reporting (May 30, 2025) on FDA’s enforcement action ending compounded semaglutide availability and impact on telehealth companies. www.reuters.com

Additional State-Specific Sources:

• Nextech Blog: State Laws Around Semaglutide (Apr 11, 2025) – State-by-state prescribing requirements www.nextech.com
• Texas Medical Board: Prescribing and Supervision Guidelines (Accessed Dec 2025) – NP/PA prescribing authority in Texas www.tmb.texas.gov
• National Law Review: Arkansas Telemedicine Regulation – Analysis of Arkansas’s strict telehealth requirements natlawreview.com
• Senator Murkowski Press Release: TREATS Act Reintroduction (Oct 28, 2025) – Federal legislation to expand telehealth access www.murkowski.senate.gov

DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.

States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of Dec 2025)

Note: State laws are constantly evolving. Federal telehealth rules for controlled substances are temporary (set to expire 12/31/2025) – an additional extension or new rule is expected. Readers should verify current regulations in their state when seeking treatment.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid